Arcus Biosciences Inc (NYSE: RCUS) on Friday, plunged -4.39% from the previous trading day, before settling in for the closing price of $10.02. Within the past 52 weeks, RCUS’s price has moved between $9.42 and $19.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 172.99% over the past five years. The company achieved an average annual earnings per share of -33.79%. With a float of $58.49 million, this company’s outstanding shares have now reached $92.20 million.
Let’s look at the performance matrix of the company that is accounted for 627 employees. In terms of profitability, gross margin is 98.06%, operating margin of -127.91%, and the pretax margin is -109.69%.
Arcus Biosciences Inc (RCUS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 44.74%, while institutional ownership is 49.40%. The most recent insider transaction that took place on Feb 27 ’25, was worth 201,200. In this transaction Director of this company bought 20,000 shares at a rate of $10.06, taking the stock ownership to the 28,400 shares. Before that another transaction happened on Feb 27 ’25, when Company’s Chief Executive Officer bought 19,800 for $10.18, making the entire transaction worth $201,465. This insider now owns 2,554,160 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.51% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 4.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -4.17 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Arcus Biosciences Inc (NYSE: RCUS) saw its 5-day average volume 0.99 million, a positive change from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 16.96%. Additionally, its Average True Range was 0.77.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 1.67%, which indicates a significant decrease from 4.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.52% in the past 14 days, which was higher than the 62.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.90, while its 200-day Moving Average is $15.27. Nevertheless, the first resistance level for the watch stands at $9.89 in the near term. At $10.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.39. If the price goes on to break the first support level at $9.39, it is likely to go to the next support level at $9.19. Assuming the price breaks the second support level, the third support level stands at $8.89.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
Market capitalization of the company is 1.01 billion based on 105,138K outstanding shares. Right now, sales total 258,000 K and income totals -283,000 K. The company made 26,000 K in profit during its latest quarter, and -94,000 K in sales during its previous quarter.
